Edwards Lifesciences Corp 4

Edwards Lifesciences CFO Theodora Mistras received large equity compensation grants on July 9, 2026, including 99,920 RSU-based common shares and options on 61,800 shares, with no open-market trades.

On July 9, 2026, Theodora Mistras, CVP and Chief Financial Officer of Edwards Lifesciences Corp, received multiple equity awards under the company’s Long-Term Stock Incentive Compensation Program, with no open-market purchases or sales. She was granted 87,595 restricted stock units (time-based RSUs) of common stock and an additional 12,325 restricted stock units, bringing her directly held common stock (or RSU-equivalent) position to 99,920 shares. She also received employee stock options for 61,800 shares at an exercise price of $91.33 per share, vesting in four equal annual installments starting one year after the grant date, and performance-based restricted stock units covering 12,325 target shares scheduled to vest on July 9, 2029 based on achievement of three-year performance goals. Using the current stock price of $92.21, the time-based and performance RSU grants together represent roughly $10.7 million in notional value (excluding any option time value), and her reported post-transaction direct holdings are worth approximately $9.2 million, underscoring a significant, compensation-driven alignment with shareholders rather than discretionary buying or selling.

Filing Facts

CIK

1099800

Ticker

EW

Form

4

Source Type

sec

Accession

0001225208-26-006578

Alert Tier

7